Sarepta Therapeutics annual total liabilities
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Sarepta Therapeutics Total Liabilities Growth & History (SRPT)
Sarepta Therapeutics's total liabilities was $2.21B for fiscal 2025.
View full Sarepta Therapeutics company overviewSarepta Therapeutics annual total liabilities history
| Fiscal year | Period ended | Total liabilities | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $2.21B | −$226.3M | −9.29% |
| 2024 | 2024-12-31 | $2.44B | $30.2M | +1.26% |
| 2023 | 2023-12-31 | $2.41B | −$338.2M | −12.33% |
| 2022 | 2022-12-31 | $2.74B | $523.5M | +23.58% |
| 2021 | 2021-12-31 | $2.22B | −$3.0M | −0.13% |
| 2020 | 2020-12-31 | $2.22B | $1.22B | +121.27% |
| 2019 | 2019-12-31 | $1.00B | $394.8M | +64.75% |
| 2018 | 2018-12-31 | $609.8M | $91.1M | +17.55% |
| 2017 | 2017-12-31 | $518.7M | $431.3M | +493.44% |
| 2016 | 2016-12-31 | $87.4M | $4.0M | +4.77% |
| 2015 | 2015-12-31 | $83.4M | $36.1M | +76.10% |
| 2014 | 2014-12-31 | $47.4M | $3.0M | +6.77% |
| 2013 | 2013-12-31 | $44.4M | −$36.9M | −45.43% |
| 2012 | 2012-12-31 | $81.3M | $59.7M | +276.56% |
| 2011 | 2011-12-31 | $21.6M | −$25.4M | −54.01% |
| 2010 | 2010-12-31 | $47.0M | — | — |
Sarepta Therapeutics quarterly total liabilities
Q4.10
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Total liabilities | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.66B | −$661.7M | −28.49% |
| Q1 2026 | 2026-03-31 | $1.67B | −$648.8M | −27.93% |
| Q4 2025 | 2025-12-31 | $2.21B | −$226.3M | −9.29% |
| Q3 2025 | 2025-09-30 | $2.17B | −$205.5M | −8.64% |
| Q2 2025 | 2025-06-30 | $2.32B | −$24.8M | −1.05% |
| Q1 2025 | 2025-03-31 | $2.32B | $59.5M | +2.63% |
| Q4 2024 | 2024-12-31 | $2.44B | $30.2M | +1.26% |
| Q3 2024 | 2024-09-30 | $2.38B | $33.5M | +1.43% |
| Q2 2024 | 2024-06-30 | $2.35B | −$37.3M | −1.56% |
| Q1 2024 | 2024-03-31 | $2.26B | −$83.8M | −3.57% |
| Q4 2023 | 2023-12-31 | $2.41B | −$338.2M | −12.33% |
| Q3 2023 | 2023-09-30 | $2.35B | −$380.0M | −13.94% |
| Q2 2023 | 2023-06-30 | $2.38B | $114.1M | +5.02% |
| Q1 2023 | 2023-03-31 | $2.35B | $147.8M | +6.72% |
| Q4 2022 | 2022-12-31 | $2.74B | $523.5M | +23.58% |
| Q3 2022 | 2022-09-30 | $2.73B | $532.6M | +24.29% |
| Q2 2022 | 2022-06-30 | $2.27B | −$3.6M | −0.16% |
| Q1 2022 | 2022-03-31 | $2.20B | −$30.5M | −1.37% |
| Q4 2021 | 2021-12-31 | $2.22B | −$3.0M | −0.13% |
| Q3 2021 | 2021-09-30 | $2.19B | $304.1M | +16.10% |
| Q2 2021 | 2021-06-30 | $2.27B | $433.8M | +23.57% |
| Q1 2021 | 2021-03-31 | $2.23B | $427.2M | +23.70% |
| Q4 2020 | 2020-12-31 | $2.22B | $1.22B | +121.27% |
| Q3 2020 | 2020-09-30 | $1.89B | $1.18B | +167.03% |
| Q2 2020 | 2020-06-30 | $1.84B | $1.19B | +183.72% |
| Q1 2020 | 2020-03-31 | $1.80B | $1.19B | +192.94% |
| Q4 2019 | 2019-12-31 | $1.00B | $394.8M | +64.75% |
| Q3 2019 | 2019-09-30 | $707.3M | $164.2M | +30.24% |
| Q2 2019 | 2019-06-30 | $648.6M | $100.5M | +18.33% |
| Q1 2019 | 2019-03-31 | $615.3M | $91.8M | +17.54% |
| Q4 2018 | 2018-12-31 | $609.8M | $91.1M | +17.55% |
| Q3 2018 | 2018-09-30 | $543.1M | $439.9M | +426.60% |
| Q2 2018 | 2018-06-30 | $548.1M | $475.7M | +657.41% |
| Q1 2018 | 2018-03-31 | $523.5M | $441.1M | +535.41% |
| Q4 2017 | 2017-12-31 | $518.7M | $431.3M | +493.44% |
| Q3 2017 | 2017-09-30 | $103.1M | $24.4M | +31.06% |
| Q2 2017 | 2017-06-30 | $72.4M | −$10.2M | −12.40% |
| Q1 2017 | 2017-03-31 | $82.4M | $8.0M | +10.74% |
| Q4 2016 | 2016-12-31 | $87.4M | $4.0M | +4.77% |
| Q3 2016 | 2016-09-30 | $78.7M | $17.2M | +27.91% |
| Q2 2016 | 2016-06-30 | $82.6M | $16.3M | +24.53% |
| Q1 2016 | 2016-03-31 | $74.4M | $32.5M | +77.36% |
| Q4 2015 | 2015-12-31 | $83.4M | $36.1M | +76.10% |
| Q3 2015 | 2015-09-30 | $61.5M | $28.7M | +87.24% |
| Q2 2015 | 2015-06-30 | $66.3M | $28.9M | +77.42% |
| Q1 2015 | 2015-03-31 | $41.9M | −$4.5M | −9.65% |
| Q4 2014 | 2014-12-31 | $47.4M | $3.0M | +6.77% |
| Q3 2014 | 2014-09-30 | $32.9M | −$24.6M | −42.86% |
| Q2 2014 | 2014-06-30 | $37.4M | −$57.4M | −60.57% |
| Q1 2014 | 2014-03-31 | $46.4M | −$59.6M | −56.23% |
| Q4 2013 | 2013-12-31 | $44.4M | −$36.9M | −45.43% |
| Q3 2013 | 2013-09-30 | $57.5M | $1.5M | +2.75% |
| Q2 2013 | 2013-06-30 | $94.8M | $76.9M | +430.03% |
| Q1 2013 | 2013-03-31 | $106.1M | $75.2M | +243.34% |
| Q4 2012 | 2012-12-31 | $81.3M | $59.7M | +276.56% |
| Q3 2012 | 2012-09-30 | $56.0M | $28.4M | +103.09% |
| Q2 2012 | 2012-06-30 | $17.9M | −$20.1M | −52.91% |
| Q1 2012 | 2012-03-31 | $30.9M | — | — |
| Q4 2011 | 2011-12-31 | $21.6M | −$25.4M | −54.01% |
| Q3 2011 | 2011-09-30 | $27.6M | — | — |
| Q2 2011 | 2011-06-30 | $38.0M | — | — |
| Q4 2010 | 2010-12-31 | $47.0M | — | — |
Sarepta Therapeutics total liabilities trends
Over the last five fiscal years, Sarepta Therapeutics's total liabilities decreased from $2.22B to $2.21B, a change of −$13.9M. The latest reported quarter, Q2 2026, shows $1.66B.
About the metric
What total liabilities mean
Total liabilities are all obligations reported on a company’s balance sheet, including debt, accounts payable, accrued expenses, deferred revenue, lease liabilities, and other current and long-term obligations.
Calculation and source
SEC-reported and calculated total liabilities
TickerStat uses total liabilities reported in company SEC filings when available. Otherwise, it calculates total liabilities as aligned total assets minus total equity for the same balance-sheet date. Total liabilities should not be confused with interest-bearing debt. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Sarepta Therapeutics source filings ↗Community posts
Novartis’ DM1 trial misses its primary endpoint
Novartis’ ($NVS) del-desiran failed to show a statistically significant improvement on the primary endpoint in the Phase III HARBOR trial for myotonic dystrophy type 1. The company will continue analysing the data and discuss next steps wit ...